SGEN - Seattle Genetics Inc Stock Price, Fair Value and News

3711.48USD Market Closed

Market Summary

USD3711.48

Market Closed

SGEN Stock Price

View Fullscreen

SGEN RSI Chart

SGEN Valuation

Market Cap

700.2B

Price/Earnings (Trailing)

-933.34

Price/Sales (Trailing)

304.4

EV/EBITDA

-1.0K

Price/Free Cashflow

-998.58

SGEN Price/Sales (Trailing)

SGEN Profitability

EBT Margin

-32.12%

Return on Equity

-29.42%

Return on Assets

-20.64%

Free Cashflow Yield

-0.1%

SGEN Fundamentals

SGEN Revenue

Revenue (TTM)

2.3B

SGEN Earnings

Earnings (TTM)

-750.2M

Breaking Down SGEN Revenue

Last 90 days

1522.6%

Trailing 12 Months

1705.6%

How does SGEN drawdown profile look like?

SGEN Financial Health

Current Ratio

2.67

SGEN Investor Care

Shares Dilution (1Y)

1.61%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	2.1B	2.2B	2.3B	0
2022	1.7B	1.8B	1.9B	2.0B
2021	2.3B	2.4B	1.7B	1.6B
2020	956.0M	1.0B	1.9B	2.2B
2019	709.3M	757.6M	801.4M	916.7M
2018	513.7M	575.7M	609.8M	654.7M
2017	416.1M	428.9M	457.9M	482.3M
2016	365.8M	384.1M	406.3M	418.1M
2015	300.6M	309.4M	317.7M	336.8M
2014	280.2M	275.0M	279.8M	286.8M
2013	219.9M	244.6M	265.8M	269.3M
2012	130.9M	166.6M	195.8M	210.8M
2011	73.2M	49.4M	54.0M	94.8M
2010	65.8M	79.7M	93.6M	107.5M
2009	0	0	0	52.0M

Get all data in R, Python etc through our Historical Stock Data APIs

About Seattle Genetics Inc

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases. It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.

CEO	Mr. David R. Epstein B.Sc., M.B.A.
WEBSITE	seagen.com
INDUSTRY	Biotechnology
EMPLOYEES	3256

Seattle Genetics Inc Frequently Asked Questions

What is the ticker symbol for Seattle Genetics Inc? What does SGEN stand for in stocks?

SGEN is the stock ticker symbol of Seattle Genetics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Seattle Genetics Inc (SGEN)?

As of Fri Apr 05 2024, market cap of Seattle Genetics Inc is 700.22 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SGEN stock?

You can check SGEN's fair value in chart for subscribers.

Is Seattle Genetics Inc a good stock to buy?

The fair value guage provides a quick view whether SGEN is over valued or under valued. Whether Seattle Genetics Inc is cheap or expensive depends on the assumptions which impact Seattle Genetics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SGEN.

What is Seattle Genetics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 05 2024, SGEN's PE ratio (Price to Earnings) is -933.34 and Price to Sales (PS) ratio is 304.4. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SGEN PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Seattle Genetics Inc's stock?

In the past 10 years, Seattle Genetics Inc has provided 0.569 (multiply by 100 for percentage) rate of return.